| SWOG/ Support |
STUDY | R E G |
O P E N |
ARM | ACCR. GOAL |
TOTAL REGS. |
REGS. LAST 12 Month |
REGS. LAST 6 Month |
REGS. LAST 3 Month |
REGS. LAST 30 DAYS |
REGS. LAST 7 DAYS |
DATE OF FIRST REG. |
# of ACT. INSTs |
# of CURR IRBs |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| SWOG | S1827-SCLC, MRI Surveillance +/- PCI | 1 | Y | 1 PCI + MRI brain surveillance | 668 | 74 | 26 | 17 | 6 | 4 | 0 | 05/04/2020 | 329 | 132 |
| 2 MRI brain surveillance | 76 | 28 | 16 | 8 | 5 | 1 | ||||||||
| 150 | 54 | 33 | 14 | 9 | 1 | |||||||||
| S1900E-KRAS G12C: Sotorasib (AMG 510) | 1 | Y | 1 Sotorasib (AMG 510) | 116 | 92 | 30 | 15 | 7 | 2 | 1 | 04/16/2021 | 318 | 123 | |
| 92 | 30 | 15 | 7 | 2 | 1 | |||||||||
| S1900G-EGFR-Mut, MET-Amp: Capmat + Osimert +/- Ramu | 1 | Y | 1 Capmatinib + Osimertinib + Ramucirumab | 66 | 1 | 1 | 1 | 1 | 1 | 0 | 05/05/2023 | 190 | 64 | |
| 1 | 1 | 1 | 1 | 1 | 0 | |||||||||
| S1914-NSCLC, High Risk Early Stg, SBRT +/- Atezo | 1 | Y | 1 Atezolizumab and SBRT | 480 | 107 | 55 | 33 | 16 | 4 | 1 | 08/13/2020 | 311 | 121 | |
| 2 SBRT | 101 | 51 | 25 | 13 | 2 | 0 | ||||||||
| 208 | 106 | 58 | 29 | 6 | 1 | |||||||||
| S1933-NSCLC, Stg II-III, RT + Atezo | 1 | Y | 1 Hypofractionated Radiotherapy | 47 | 28 | 6 | 2 | 0 | 0 | 0 | 01/13/2021 | 144 | 50 | |
| 28 | 6 | 2 | 0 | 0 | 0 | |||||||||
| 2 | Y | 2 Atezolizumab | 23 | 7 | 3 | 2 | 0 | 0 | 01/13/2021 | |||||
| 23 | 7 | 3 | 2 | 0 | 0 | |||||||||
| S2302-NSCLC, Stg IV or Recur, Ramu + Pembro vs SoC | 1 | Y | 1 Standard of Care (Inv. Choice) | 700 | 14 | 14 | 14 | 14 | 9 | 2 | 03/14/2023 | 291 | 109 | |
| 2 Ramucirumab + Pembrolizumab | 15 | 15 | 15 | 15 | 8 | 2 | ||||||||
| 29 | 29 | 29 | 29 | 17 | 4 | |||||||||
| LUNGMAP-NSCLC, Adv, Master | 1 | Y | 1 Biomarker Profiling | 3062 | 556 | 251 | 134 | 34 | 9 | 02/06/2019 | 414 | 181 | ||
| 3062 | 556 | 251 | 134 | 34 | 9 | |||||||||
| Yes | A081801-ALCHEMIST4, ALK and EGFR negative, Chemo-IO | 1 | E | Total Registrations | 58 | 25 | 10 | 8 | 1 | 0 | 10/20/2020 | 407 | 174 | |
| 58 | 25 | 10 | 8 | 1 | 0 | |||||||||
| A151216-ALCHEMIST0 - screening | 1 | E | Total Registrations | 945 | 33 | 12 | 8 | 2 | 0 | 12/16/2014 | 501 | 244 | ||
| 945 | 33 | 12 | 8 | 2 | 0 | |||||||||
| E4512-ALCHEMIST2, ALK mut, Crizotinib | 1 | E | Total Registrations | 16 | 0 | 0 | 0 | 0 | 0 | 02/29/2016 | 502 | 231 | ||
| 16 | 0 | 0 | 0 | 0 | 0 | |||||||||
| EA5163-NSCLC, Immunotherapy +/- 2nd line therapy | 1 | E | Total Registrations | 65 | 15 | 10 | 6 | 1 | 1 | 05/30/2019 | 378 | 133 | ||
| 65 | 15 | 10 | 6 | 1 | 1 | |||||||||
| EA5181-NSCLC, Unresect Stg 3, Chemo/RT+/-MED4736 | 1 | E | Total Registrations | 62 | 22 | 12 | 7 | 4 | 0 | 08/03/2020 | 309 | 119 | ||
| 62 | 22 | 12 | 7 | 4 | 0 | |||||||||
| 2 | E | Total Registrations | 48 | 21 | 6 | 2 | 0 | 0 | 08/03/2020 | |||||
| 48 | 21 | 6 | 2 | 0 | 0 | |||||||||
| EA5182-NSCLC, Met EGFR mut, AZD9291+Beva vs AZD9291 | 1 | E | Total Registrations | 7 | 5 | 1 | 1 | 0 | 0 | 04/28/2021 | 179 | 79 | ||
| 7 | 5 | 1 | 1 | 0 | 0 | |||||||||
| EA5191-NSCLC, Cabozantinib +/- Nivolumab vs Chemo | 0 | E | Total Registrations | 10 | 4 | 1 | 1 | 0 | 0 | 11/02/2020 | 196 | 80 | ||
| 10 | 4 | 1 | 1 | 0 | 0 | |||||||||
| 1 | E | Total Registrations | 8 | 3 | 1 | 1 | 0 | 0 | 11/02/2020 | |||||
| 8 | 3 | 1 | 1 | 0 | 0 | |||||||||
| NRGLU002-LUNG, Limited Met NSCLC, MST vs LCT + MST | 1 | E | Total Registrations | 2 | 0 | 0 | 0 | 0 | 0 | 11/06/2019 | 289 | 118 | ||
| 2 | 0 | 0 | 0 | 0 | 0 | |||||||||
| No | A082002-Lung, Adv, Systemic Tx +/- SBRT | 1 | E | Total Registrations | 3 | 3 | 2 | 1 | 0 | 0 | 10/12/2022 | 158 | 62 | |
| 3 | 3 | 2 | 1 | 0 | 0 | |||||||||
| A151216-ALCHEMIST0 - screening | 0 | E | Total Registrations | 957 | 33 | 12 | 8 | 2 | 0 | 12/16/2014 | 501 | 244 | ||
| 957 | 33 | 12 | 8 | 2 | 0 | |||||||||
| A171901-NSCLC, > 70 Years Old, Pembro +/- Chemo | 1 | E | Total Registrations | 1 | 1 | 0 | 0 | 0 | 0 | 09/13/2022 | 187 | 78 | ||
| 1 | 1 | 0 | 0 | 0 | 0 | |||||||||
| NRGLU005-LUNG, LS-SCLC, ChemoRT v ChemoRT+Atezo | 1 | E | Total Registrations | 13 | 0 | 0 | 0 | 0 | 0 | 08/16/2019 | 386 | 134 | ||
| 13 | 0 | 0 | 0 | 0 | 0 | |||||||||
| NRGLU006-Meso, Stg I-IIIA, Pleurectomy +/- Adj RT | 1 | E | Total Registrations | 2 | 2 | 0 | 0 | 0 | 0 | 07/07/2022 | 77 | 24 | ||
| 2 | 2 | 0 | 0 | 0 | 0 | |||||||||
| 2 | E | Total Registrations | 2 | 2 | 1 | 1 | 0 | 0 | 07/07/2022 | |||||
| 2 | 2 | 1 | 1 | 0 | 0 | |||||||||
| R1308-Lung, Stg II/III, Photon vs Proton Chemo RT | 1 | E | Total Registrations | 1 | 0 | 0 | 0 | 0 | 0 | 09/30/2021 | 42 | 30 | ||
| 1 | 0 | 0 | 0 | 0 | 0 | |||||||||
| Study | Registration/Phase | Open Date | # of ACT. INSTs |
# of CURR IRBs |
|---|---|---|---|---|
| S1900F RET Fusion: Carbo + Peme +/- Selpercatinib | 1 Randomization | 25-Jul-22 | 296 | 96 |
| EA5191 NSCLC, Cabozantinib +/- Nivolumab vs Chemo | 2 Registration | 22-May-20 | 196 | 80 |